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The limitations of existing tuberculosis diagnostic tools are significantly hampering tuberculosis control
efforts, most noticeably in areas with high prevalence of human immunodeficiency virus (HIV) infection and
antituberculosis drug resistance. However, renewed global interest in tuberculosis research has begun to bear
fruit, with several new diagnostic technologies progressing through the development pipeline. There are
significant challenges in building a sound evidence base to inform public health policies because most
diagnostic research focuses on the accuracy of individual tests, with often significant limitations in the design,
conduct, and reporting of diagnostic accuracy studies. Diagnostic accuracy studies may not be appropriate to
guide public health policies, and clinical trials may increasingly be required to determine the incremental value
and cost-effectiveness of new tools. The urgent need for new diagnostics should not distract from pursuing
rigorous scientific evaluation focused on public health impact.
Global control of the tuberculosis epidemic is a public
health priority [1, 2]. The targets for reduction in tu-
berculosis prevalence and mortality linked to the Mil-
lennium Development Goals and enshrined in the STOP
TB Global Plan 2006–2015 will not be achieved with
current interventions [3, 4]. There is an acute need for
improved tuberculosis diagnostics as one critical com-
ponent of the public health response to the tuberculosis
epidemic.
The rapid growth of the human immunodeficiency
virus (HIV) epidemic and the emergence of antitu-
berculosis drug resistance have highlighted the major
deficiencies in current diagnostic technologies both
for pathogen detection and for diagnosis of drug
resistance [5]. In most high-burden countries, sputum
smear microscopy remains the principal tool for di-
agnosing active disease; however, operationally, its sensi-
tivity for pulmonary tuberculosis can be as low as 20%
[6, 7]. Sputum culture and drug susceptibility testing are
available in certain settings, but their impact is limited by
the long duration and complexity of the laboratory pro-
cesses [8]. Additional challenges are faced in developing
diagnostics for extrapulmonary tuberculosis, pediatric
tuberculosis, and latent tuberculosis infection [9–11].
The STOP TB Global Plan 2006–2015 included the
target that, ‘‘by 2010, simple, robust, affordable tech-
nologies for use at peripheral levels of the health system
will enable rapid, sensitive detection of active tubercu-
losis at the first point of care’’ [4, p. 24]. Although this
has not been achieved, there have been developments in
the tuberculosis diagnostic field, and promising tech-
nologies have entered the clinical sphere [6, 12–15].
Most promising has been the Xpert MTB/RIF system,
an automated molecular test that simultaneously detects
Mycobacterium tuberculosis and mutations associated
with rifampicin resistance [16, 17]. It is hoped that the
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renewed global focus on tuberculosis will in the next few years
lead to the further proliferation of diagnostic technologies in
parallel with advances in therapeutics and vaccines.
It is the responsibility of the global scientific community to
correctly evaluate these new technologies so that proven effective
and cost-effective diagnostics can be adopted, thus generating
the greatest public health impact. The importance of diagnostic
research in the overall tuberculosis research agenda has been
highlighted by many different groups [2, 15, 18–22]. However,
huge gaps in funding for tuberculosis research and tuberculosis
control remain [1, 2, 23]; this should force us to rethink how
diagnostic research can be most effectively targeted and ratio-
nalized to inform public health policies.
This article focuses on the framework for evaluation of new
diagnostics: at the outset, we look at the potential benefits of
new diagnostics, and then we discuss different methodologies to
evaluate diagnostic performance with a view to their ultimate
implementation. Our focus throughout is on diagnostic tests for
detection of active tuberculosis disease and/or drug resistance in
high-burden countries.
POTENTIAL IMPACT OF NEW TUBERCULOSIS
DIAGNOSTICS
It has been hypothesized that a test more sensitive than sputum
microscopy for tuberculosis would be the diagnostic inter-
vention that would alleviate the greatest burden of infectious
disease in developing countries [24]. More specifically, one
mathematical model of the global tuberculosis epidemic sug-
gested that a new rapid diagnostic test with 100% sensitivity,
100% specificity, and 100% access could prevent 625 000 deaths
annually (equivalent to 36% of all tuberculosis-related deaths)
[25]. Other models have derived fairly consistent estimates of
mortality reductions of 17%–23% from a more sensitive rapid
tuberculosis diagnostic, despite exploring different epidemics
[26–28]. In one model, the estimated benefit in terms of mor-
tality from a new diagnostic test was equivalent in magnitude to
that expected from a novel vaccine or an optimized 2-month
treatment regimen for active disease [26]. This highlights 2 im-
portant points: (1) no single intervention will have the impact
required to meet tuberculosis control targets; thus, scaled-up
investment in research and implementation of diagnostics,
drugs, and vaccines will be required; and (2) because new di-
agnostics could have an equivalent impact to new drugs or
vaccines, evaluation of diagnostics should be as rigorous as
evaluation of drugs and vaccines.
EXISTING FRAMEWORK FOR TUBERCULOSIS
DIAGNOSTIC RESEARCH AND DEVELOPMENT
The fact that sputum smear microscopy remains the cornerstone
of tuberculosis diagnosis in most high-burden countries is
testament to the relative paucity of research and development in
the diagnostic arena and the failure to translate research findings
into policy. In medicine broadly, diagnostic research tends to be
performed in stepwise fashion, with basic science leading to
laboratory-based performance evaluation and then to clinical
studies (Figure 1) [29]. This structure inherently tends to ex-
clude the perspectives of end users in the conception and de-
velopment of diagnostics, although more recently in the
tuberculosis field, organizations have assisted this process by
defining the ideal specifications for a point-of-care test [30].
In the tuberculosis field, the process of diagnostic de-
velopment has rarely gone beyond diagnostic accuracy studies to
assess the impact in clinical practice on clinical decision making,
patient outcomes, and health system costs [13, 31, 32]. This is in
part explained by the fact that the regulatory framework for in
vitro diagnostic devices usually does not require evidence be-
yond performance data. Diagnostic accuracy studies are an
important part of the evaluation process. However, there is
much potential for bias in such studies, and diagnostic accu-
racy might vary widely between different clinical settings and
populations [33–36].
In the field of diagnostic accuracy research, there have been
certain key initiatives aimed at improving and standardizing
research methodologies and reporting: the guidelines for di-
agnostic evaluation produced by the TDR Diagnostics Evaluation
Expert Panel (DEEP) [37], the Quality Assessment of Diagnostic
Figure 1. Stepwise approach to evaluation of diagnostic technologies.
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Accuracy Studies (QUADAS) tool [38], and the Standards for
the Reporting of Diagnostic Accuracy Studies (STARD) ini-
tiative [39, 40]. The DEEP guidelines outline best practice in
the design and conduct of diagnostic evaluations, with focus on
performance characteristics and operational feasibility. QUA-
DAS is a quality assessment tool to be used specifically for the
assessment of diagnostic accuracy studies included in system-
atic reviews. The tool consists of 14 items (Figure 2); the ma-
jority involve sources of bias, with a few relating to variability
and quality of reporting. The objective of the STARD initiative
is to improve the quality of reporting of diagnostic accuracy
studies. The 25-item checklist (Figure 3) allows the reader to
judge the potential for bias (internal validity) and the gener-
alizability and applicability (external validity) of the study.
A systematic review that used both QUADAS and STARD
criteria to assess tuberculosis diagnostic accuracy studies pub-
lished during 2004–2006 showed significant deficiencies in
methodology and reporting of studies [41]. Unfortunately, more
widespread use of the STARD system has not been apparent in
recent years. As a further example, of the 10 published studies
evaluating the diagnostic accuracy of the Genotype MTBDRplus
assay (published during 2007–2010) [42–51], only one manu-
script explicitly mentions STARD [51]. Additional efforts are
required by researchers, research funders, journal editors, and
policy makers to encourage the use of these tools, with the aim
of improving the quality and validity of this element of the
evidence base.
THE NEED FOR HIGH-QUALITY EVIDENCE TO
INFORM PUBLIC HEALTH POLICIES
Public health policies and guidelines are now usually informed
by a systematic approach to judging the relevant evidence. In the
tuberculosis field, the World Health Organization (WHO) con-
venes expert groups to assess the available evidence for a specific
intervention (eg, diagnostic test), and this group then presents
their findings to the WHO Strategic and Technical Advisory
Group for Tuberculosis (STAG-TB) for consideration and en-
dorsement. The system to assess the evidence now adopted by
many organizations, including WHO, is the Grading of Recom-
mendations Assessment, Development, and Evaluation (GRADE)
system, which incorporates judgments on the quality of evidence
(high, moderate, low, or very low) and on the strength of any
recommendation (initially categorized as strong or weak; now
incorporates ‘‘conditional,’’ whereby national programs should
consider implementation based on their own situation) [52, 53].
The GRADE system is based around the concept of patient-
important outcomes, and as such, evidence from diagnostic
interventions creates additional challenges. Studies using in-
direct outcomes (eg, diagnostic accuracy studies) will usually
provide lower-quality evidence because of the uncertainty about
outcomes important to patients and the potential for bias [54].
It is important to be clear that the rating of low quality in this
context does not necessarily imply that studies were conducted
poorly, but that data from the study are not optimal for deriving
public health recommendations.
GOING BEYOND DIAGNOSTIC ACCURACY
STUDIES—THE NEED FOR IMPACT DATA
In the STOP TB New Diagnostics Working Group blueprint
for the evaluation of diagnostics, the next step after diagnostic
accuracy studies are demonstration studies, which include
patient outcomes (Figure 4) [55]. These demonstration studies
are designed to assess the scaled-up test performance and to
determine patient-level outcomes. This is the stage of the
evaluation process that should start to inform policy. It is
stated in this document that patient-important outcomes
should be assessed (eg, time to initiation of treatment, time to
smear and/or culture conversion, and treatment outcome) and
Figure 2. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool.
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that ‘‘these impact-related data should be compared to his-
torical data recorded prior to implementation of the new test in
routine clinical practice’’ [55, p. 62]. This use of historical data
is problematic as a method of assessing any health care in-
tervention and would not generally be accepted by regulatory
bodies in the field of drugs or vaccines [56]. It is difficult to be
Figure 3. Standards for the Reporting of Diagnostic Accuracy Studies (STARD) checklist.
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sure that any comparison is fair; there are potential sources of
bias, and consequently, the risk is that the value of the in-
tervention can be exaggerated.
Two organizations that have been instrumental in driving
forward development and evaluation of diagnostic technologies
for tuberculosis are the Foundation for Innovative New Diag-
nostics and the WHO TDR program (Special Programme for
Research and Training in Tropical Diseases). Demonstration
studies are key elements of their tuberculosis projects, which aim
to determine the feasibility, impact, and cost-effectiveness of the
diagnostic test under evaluation. The evidence from these studies
is a key element assessed by the expert groups and reported to
STAG-TB. If we take the example of the Genotype MTBDRplus
assay, preliminary data regarding patient-important outcomes
from the South African demonstration projects seemed rela-
tively disappointing because the median turnaround times did
not meet their predefined objective of 7 days; of the patients
with multidrug-resistant tuberculosis who were identified, only
28% were started on appropriate therapy on the basis of the test
result (42% had therapy delayed until results of conventional
drug susceptibility testing were available) [57]. Although these
results were based only on preliminary data analysis and are
understandable during implementation of a new technology,
there has, to our knowledge, been no further published evi-
dence from high-burden settings on patient-important outcomes.
However, the test has been introduced into routine practice in
some countries, and its use is now being scaled up [58].
It is generally considered that the optimal methodology for
assessing the clinical impact of any intervention, including di-
agnostics, is the randomized controlled trial (RCT) [59–61].
This is the methodology least prone to bias in estimating the
benefits and risks of any intervention. Data from RCTs can
additionally be used to perform economic evaluation, a step of
major importance for policy makers. The relative shortage of
RCTs in diagnostic research, in contrast to therapeutic and
vaccine research, is likely to be explained by a combination of
factors: lack of emphasis on this level of evidence by manu-
facturers and regulatory authorities, limited funding and poor
coordination of diagnostic research, and logistical and ethical
challenges. There are features specific to diagnostic trials that
complicate trial design and implementation. In a tuberculosis
diagnostic study, the population of interest might be persons
with suspected pulmonary tuberculosis (eg, individuals with
cough). Inevitably, the majority of participants will not have
tuberculosis; thus, the potential effect size on the total cohort
resulting from improved diagnosis is relatively small. However,
we have to include the entire cohort in a trial if we want to
capture comprehensive outcome data (to balance benefits and
harms).
To reveal the value of well-designed RCTs in diagnostic re-
search, it is worthwhile to stop studying tuberculosis and con-
sider malaria, another global health priority. Malaria rapid
diagnostic tests (RDTs) have been shown to have good di-
agnostic accuracy [62], and mathematical models have sug-
gested that implementation of RDTs could lead to significant
public health benefits in settings where malaria is endemic [63].
Trials were designed to assess the performance of the tests in
a field setting and to measure the impact on health care pro-
viders, therapeutic decisions, and patient outcomes [64–67].
Three of these trials showed that, despite good diagnostic ac-
curacy, there was no reduction in incorrect antimalarial treat-
ment with the use of RDTs [64–66]; of more concern, one trial
even showed a significant reduction in correct antimalarial
treatment [66]. These trials have provided vital information for
the further development and implementation of RDTs. The
results of these trials highlight the fact that a diagnostic test is
only ever a vehicle to guide therapies; it is never of therapeutic
benefit, and it is the treatment decision that will impact on
patient outcomes.
CONCEPTUALIZING CLINICAL TRIALS OF
TUBERCULOSIS DIAGNOSTICS
The first step in any trial is to determine the hypothesis that is to
be tested because this will inform the trial design. It is important
to consider the likely position of the new test in the diagnostic
Figure 4. The pathway for evaluation of new diagnostics (from the STOP TB New Diagnostic Working Group).
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process. In the case of a test for active pulmonary tuberculosis,
we need to decide how the test will be introduced in the existing
diagnostic structure, which includes sputum microscopy, spu-
tum culture, drug-susceptibility testing, and chest radiography.
It could be proposed as a replacement for$1 of these tests, as an
addition to these tests, or as a means of triage, for example, to
target sputum culture and/or drug-susceptibility testing. This
decision is in turn likely to depend on the proposed benefits of
the new test (eg, whether it is more rapid, more sensitive, more
specific, less technical, safer, or less expensive). Furthermore, we
need to consider the outcomes of interest, whether related to
benefit or harm; these may be appropriate or inappropriate
commencement of tuberculosis treatment, outcomes during
treatment (smear or culture conversion), final treatment out-
comes (cure or completion), and mortality.
One possible reason to explain the lack of RCTs in diagnostic
research is the perception that diagnostic tests carry minimal or
no risk. Although the test is unlikely to harm the patient, the
consequences of the test (eg, the therapeutic decision) may
confer harm, as shown in the example of RDTs of malaria. What
risks might we expect in a trial of a tuberculosis diagnostic?
Consider a hypothetical trial comparing clinical outcomes be-
tween a rapid molecular tuberculosis test and the standard-
of-care diagnostic pathway (Figure 5). At a basic level, this trial
will tell us whether the benefits from earlier correct diagnosis
or exclusion of tuberculosis outweigh the risks from incorrect
classification of disease (false-negative or false-positive results).
The benefits would seem to be self-evident but need to be
quantified. The risks are more complicated and will be context
specific. False-negative diagnoses will result in appropriate
treatment being withheld, with potential for poorer outcomes.
False-positive diagnoses also carry risk, however, because alter-
native diagnoses may not be considered and, therefore, not
treated, and patients may be exposed to potentially toxic ther-
apy. For diagnosis of drug resistance, the risks from incorrect
classification are even more complicated. False-negative results
of genotypic testing may lead to inappropriate treatment with
first-line regimens, with consequent adverse outcomes, in-
cluding amplification of drug resistance. False-positive results
may lead to inappropriate treatment with multidrug-resistant
tuberculosis regimens, with lower efficacy against sensitive
strains and with risks of severe toxicity.
These examples highlight another challenge with tubercu-
losis diagnostic research (and common to much diagnostic
research), which is the lack of a perfect gold standard with
which to compare new tests. If our new test is potentially more
sensitive than the existing test (as might be the case with mo-
lecular tests, compared with sputum culture), this will affect
any analysis. The lack of a gold standard often requires a con-
struct gold standard that comprises information from the ref-
erence test with additional clinical information and follow-up
information [68]. Of further concern, discrepancies between
phenotypic and genotypic drug-susceptibility results can be
extremely difficult to interpret, and it is not always clear which
is the more reliable measure of drug resistance [69]. In many
ways, these issues reinforce the need for well-designed clinical
trials because thorough interpretation of the tests may only be
possible with meticulously collected baseline and follow-up
clinical data.
PRACTICAL TRIAL DESIGNS
If the outcomes of interest are individual-level outcomes (eg,
treatment initiation and mortality), a clinical trial with individual
randomization would be the logical and statistically most effi-
cient design. However, because there will be information re-
garding the diagnostic performance from the laboratory-based
evaluation, the question arises, if the test is shown to have
comparable accuracy to an existing test but has other advan-
tages (ie, more rapid and/or less invasive), is it ethical to
conduct an RCT with individual randomization? Critical to this
decision is whether there is equipoise regarding the clinical
outcome. Equipoise with regard to clinical outcomes of a di-
agnostic strategy arises, for example, when the consequences of
misdiagnosis are severe (eg, HIV-infected patients who receive
a misdiagnosis of tuberculosis who are dying of another
HIV-related illness) or when failure to diagnose does not lead
to mistreatment or poorer outcomes (eg, patients prescribed
tuberculosis treatment regardless of the test result).
Individual randomization may, however, present consider-
able logistical challenges in certain health care settings, and for
this reason, cluster randomized designs may be considered with
Figure 5. Potential impact of false-positive and false-negative tubercu-
losis diagnoses in a hypothetical trial comparing a rapid molecular test
to tuberculosis culture.
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health care units (eg, hospitals, clinics, and mobile teams) as
clusters. Cluster randomized designs are increasingly used in
public health research. The principal reasons for considering
such a design are as follows: if the intervention is to be delivered
to groups rather than individuals, if the outcome is to be mea-
sured at a population level, or to avoid contamination by in-
dividuals in the same community who are randomized to
different trial arms [70]. However, there is also an acceptance
that cluster randomization may also be appropriate in settings
where it offers greater logistical convenience, compared with an
individually randomized trial, although cluster RCTs generally
require larger sample sizes and have added challenges in design,
analysis, and ethics [70–72].
A further modification of the cluster randomized design is the
phased implementation or stepped-wedge design [70, 73]. The
key features of this design are that all clusters receive the in-
tervention by the end of the trial, and the order in which the
clusters receive the intervention is decided at random. This is
particularly appropriate when there is preexisting evidence that
the intervention may have a beneficial effect and when assigning
clusters to the control arm for the duration of the trial might be
ethically unacceptable. This might be particularly suited to
evaluation of certain diagnostic technologies, for which there is
evidence from initial diagnostic accuracy studies that suggests
beneficial effect.
If randomization is not deemed to be appropriate or feas-
ible, alternative prospective trial designs, often termed quasi-
experimental designs, may still be able to generate evidence on
the effectiveness of diagnostics [74]. An example would be the
pre- and postimplementation study in which outcomes are
measured during a pre-intervention phase and subsequently
during a postintervention phase. Although the lack of ran-
domization threatens the internal validity (no firm conclusion
can be made with regard to the effect of the intervention unless
the effect size is large), there may conversely be a gain in external
validity (improved generalizability of findings if fewer patients
are excluded than in conventional RCTs).
Retrospective studies may be the only methodology to obtain
outcome data in circumstances in which a diagnostic is widely
implemented on the basis of performance characteristics. Such
pre- and postimplementation analyses have been used in high-
resource settings to estimate the impact of molecular resistance
testing on detection and treatment of multidrug-resistant tu-
berculosis [75, 76].
Whether a clinical trial is justified in the evaluation of diag-
nostics will ultimately depend on the balance between the
benefit to be gained by accurately establishing the impact of
a new tool and the costs of running a large clinical trial and
potentially delaying full-scale implementation of an effective
intervention. These decisions are not straightforward, and col-
laboration between scientists and policy makers is vital to de-
termine when diagnostic trials are necessary.
CONCLUSIONS
Recent developments in tuberculosis diagnostics have led to
much optimism, but we still lack the tools that meet the needs of
patients in high-burden countries. The next 10–20 years will
hopefully see further developments in diagnostic technology.
We need to ensure that the framework for evaluating diagnostic
tools is best suited to ensuring that the tools with the greatest
public health impact and cost-effectiveness are implemented
and that those with minimal impact are developed further or are
discarded. Diagnostic accuracy studies are an important early
step in the evaluation process but do not produce sufficient
evidence to inform public health policies. Well-designed pro-
spective studies (including RCTs) should be integrated in the
research pathway to provide reliable information on therapeutic
impact, patient outcomes, and cost-effectiveness. This new era
of tuberculosis diagnostics should be accompanied by a new era
for diagnostic research focused clearly on the evaluation of
public health impact.
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